TriNutra received approval for a U.S. patent which protects its orally deliverable product, ThymoQuin, a combination of thymoquinone extracted from black seed oil and omega-3 fatty acids in different forms, such as EPA and DHA, in at least a 1:7 ratio.
 
The patented composition contains the two actives at just the right relative amounts to maximize its beneficial anti-inflammatory effects, the patent reads. Thymoquinone is one of the main actives in black seed oil, and is recognized for its ability to support a balanced inflammatory response, improve mitochondrial activity such as ATP production, and deliver antioxidant capacity and antimicrobial effects, according to the company.
 
One preclinical study supports the role that Thymoquin has in supporting immune system and acting as an antioxidant. The combination has also been evidenced in a human clinical trial to have a potential role in supporting a healthy gut microbiome.
 
“We are thrilled to announce the approval of our patent which shows strong support to raise awareness of the many benefits of black seed oil, and now, this further demonstrates its powerful synergistic impacts,” said Morris Zelkha, CEO of TriNutra. “Additional research has shown that ThymoQuin, although effective on its own, can also potentiate the impact of other well-known ingredients such as astaxanthin, hemp oil, lutein, beta-carotene, and vitamin D.”
 
ThymoQuin is also the first full-spectrum, cold-pressed black seed oil standardized to three percent thymoquinone, and a very low content of free fatty acids, TriNutra reports. This low free fatty acid content aids in preventing degradation of thymoquinone and maintaining stability for optimal activity.